Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts.
The ethyl-N-nitrosourea-induced rat glioma N32 was treated with the mutagenic compound N-methyl-N'-nitro-N-nitrosoguanidine and the surviving cells cloned by limited dilution. Out of 20 clones tested 8 did not produce tumors subcutaneously even after challenge doses 3 log units above the minimal tumor dose for N32. All of 5 clones grew in a retarded manner intracerebrally but produced tumors in some animals. Preimmunizations with three of the rejected clones (tum-) gave protection against subcutaneous and intracerebral isografts of the unmutated N32. This effect could be enhanced if the cells used for immunizations were pretreated with interferon gamma (IFN gamma) for 48 h. If immunizations were started subsequent to challenge, only immunization with one of two tested tum- clones pretreated with IFN gamma induced significant rejection against intracerebral N32 isografts. Both N32 and its tum- clones were MHC class I positive and MHC class II negative. IFN gamma treatment enhanced the MHC class I expression with 20%-90% on the tum- clones and with 40% on N32. MHC class II expression could be induced on N32 cells after 7 days of IFN gamma treatment but not on any of the tum- clones tested. We conclude that the enhancing effect of IFN gamma treatment on tumor isograft rejection may depend on up-regulation of MHC class I but not of MHC class II. This investigation demonstrates that it is possible to induce rejection of weakly immunogenic intracerebral brain tumors by immunization with selected highly immunogenic tumor cell mutants. In conjunction with relevant cytokines, the cross-protective effect of these tum- variants might be further enhanced and serve as a model for immunotherapy against malignant human brain tumors.
Department of Tumorimmunology, Wallenberg Laboratory, University of Lund, Sweden.
P
P
Siesjö
E
E
Visse
M
M
Lindvall
L
L
Salford
H O
HO
Sjögren
D000818:Animals; D001932:Brain Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D005260:Female; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D005910:Glioma / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D006084:Graft Rejection; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis; D007114:Immunization; D007167:Immunotherapy; D007371:Interferon-gamma / Q000276:immunology / Q000627:therapeutic use; D008297:Male; D008769:Methylnitronitrosoguanidine / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D051381:Rats; D011916:Rats, Inbred F344; D016019:Survival Analysis; D015996:Survival Rate; D013997:Time Factors; D014185:Transplantation, Isogeneic; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D008769:Methylnitronitrosoguanidine; D007371:Interferon-gamma